Tursian Skincare officially launches, introducing a new benchmark in results-driven skincare. Backed by science, powered by precision formulation, and rooted in a deep respect for the skin's natural ...

Explore the future of the pharmaceutical industry with this comprehensive report. Delve into key trends via regulatory, clinical, and market analyses. Essential for investors, new entrants, and pharma ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Key growth drivers include increased healthcare spending, the rise of chronic diseases, and advancements in nanotechnology.

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

(Reuters) -Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment ...

Pheochromocytomas and paragangliomas (PCPG) are highly vascular neuroendocrine tumors originating from chromaffin cells of the adrenal medulla or from neural crest-derived cells located outside the ...